Newsletter
Language
Language:
 
News
Archival Issues
Volume 19, 2017
Volume 18, 2016
Volume 17, 2015
Volume 16, 2014
Volume 15, 2013
Volume 14, 2012
Volume 13, 2011
Volume 12, 2010
Volume 11, 2009
Volume 10, 2008
Volume 9, 2007
Volume 8, 2006
Volume 7, 2005
Volume 6, 2004
Volume 5, 2003
Volume 4, 2002
Volume 3, 2001
Volume 2, 2000
Volume 1, 1999
Search
 » 
Journal Abstract
 
Cost-effectiveness Analysis of Treatment of Osteoporotic Fractures in Relation to FRAX Algorithm in a Sample of Polish Population
Jarosław Amarowicz, Dorota Bolisęga, Jakub Rutkowski, Anna Kumorek, Edward Czerwiński
Ortop Traumatol Rehabil 2015; 17(1):59-69
ICID: 1143537
Article type: Original article
IC™ Value: 3.00
Abstract provided by Publisher
 
Background. The increasing incidence of osteoporotic fractures is becoming a growing burden on the health service. Due to the high cost of treatment, these fractures require a broader look at the underlying pro blem. The aim of the study was to assess the 10-year probability of hip fracture or any other major osteoporotic fracture at which the treatment becomes cost-effective
Material and methods. This was a retrospective study of a group of 1,024 patients. The cost-effectiveness of pharmacological low-energy fracture prevention was analyzed by means of the medication defined as the reimbursement limit basis in the reimbursement limit group 147.0. (medications used in bone diseases) in July 2013 (Alendrogen 70 mg). 3- and 5-year therapies were analysed. The outcome was compared with the results of FRAX® (ofr the Polish and British population) in every patient.
Results. The model for calculating cost-effectiveness showed that treatment after the age of 50 until the age of 60-65 years is cost-effective at a similar level of 10-year major fracture probability (regardless of treatment duration). After the age of 65, there is a clear decline in the profitability of the therapy. The results indicate that, for the population of women aged >50 years, the treatment is cost-effective when the 10-year major fracture probability equals 5.1% and 6% for a 3- and 5-year therapy, respectively.
Conclusions. 1. The study showed pharmacological treatment to be cost-effective in a large group of patients forming the study population. 2. The analysis also revealed a strong correlation between study results and the specific tool employed to define fracture probability.

ICID 1143537

DOI 10.5604/15093492.1143537
PMID 25759156 - click here to show this article in PubMed
 
FULL TEXT 1626 KB


Related articles
  • in IndexCopernicus™
         FRAX [0 related records]
         cost-effectiveness [0 related records]
         Probability [1376 related records]
         fracture [32 related records]
         Osteoporosis [288 related records]

  • Related articlesin PubMed database
  • in PubMed database [ related records]


  •  

    Copyright © Ortopedia Traumatologia Rehabilitacja  2017
    Page created by Index Copernicus Ltd. All Rights reserved.